Joshua Reed - Net Worth and Insider Trading

Joshua Reed Net Worth

The estimated net worth of Joshua Reed is at least $145,779 dollars as of 2024-05-01. Joshua Reed is the CFO of Aldeyra Therapeutics Inc and owns about 35,774 shares of Aldeyra Therapeutics Inc (ALDX) stock worth over $145,779. Details can be seen in Joshua Reed's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Joshua Reed has not made any transactions after 2019-09-05 and currently still holds the listed stock(s).

Transaction Summary of Joshua Reed

To

Joshua Reed Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Joshua Reed owns 3 companies in total, including Aldeyra Therapeutics Inc (ALDX) , Scholar Rock Holding Corp (SRRK) , and Omega Therapeutics Inc (OMGA) .

Click here to see the complete history of Joshua Reed’s form 4 insider trades.

Insider Ownership Summary of Joshua Reed

Ticker Comapny Transaction Date Type of Owner
ALDX Aldeyra Therapeutics Inc 2019-09-05 Chief Financial Officer
SRRK Scholar Rock Holding Corp 2022-05-26 director
OMGA Omega Therapeutics Inc 2022-05-23 Chief Financial Officer

Joshua Reed Latest Holdings Summary

Joshua Reed currently owns a total of 1 stock. Joshua Reed owns 35,774 shares of Aldeyra Therapeutics Inc (ALDX) as of September 5, 2019, with a value of $145,779.

Latest Holdings of Joshua Reed

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
ALDX Aldeyra Therapeutics Inc 2019-09-05 35,774 4.08 145,779

Holding Weightings of Joshua Reed


Joshua Reed Form 4 Trading Tracker

According to the SEC Form 4 filings, Joshua Reed has made a total of 1 transactions in Aldeyra Therapeutics Inc (ALDX) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Aldeyra Therapeutics Inc is the acquisition of 3,200 shares on September 5, 2019, which cost Joshua Reed around $15,072.

Insider Trading History of Joshua Reed

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Joshua Reed Trading Performance

GuruFocus tracks the stock performance after each of Joshua Reed's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Joshua Reed is -4.36%. GuruFocus also compares Joshua Reed's trading performance to market benchmark return within the same time period. The performance of stocks bought by Joshua Reed within 3 months outperforms 0 times out of 1 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Joshua Reed's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Joshua Reed

Average Return

Average return per transaction

Outperforming Transactions

1 out of 1 outperforming transactions.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Return(%) 11.68
Relative Return to S&P 500(%) 12.49

Joshua Reed Ownership Network

Ownership Network List of Joshua Reed

No Data

Ownership Network Relation of Joshua Reed


Joshua Reed Owned Company Details

What does Aldeyra Therapeutics Inc do?

Who are the key executives at Aldeyra Therapeutics Inc?

Joshua Reed is the Chief Financial Officer of Aldeyra Therapeutics Inc. Other key executives at Aldeyra Therapeutics Inc include 10 percent owner Perceptive Life Sciences Master Fund Ltd , Chief Development Officer Stephen Machatha , and director & President and CEO Todd C Brady .

Aldeyra Therapeutics Inc (ALDX) Insider Trades Summary

Over the past 18 months, Joshua Reed made no insider transaction in Aldeyra Therapeutics Inc (ALDX). Other recent insider transactions involving Aldeyra Therapeutics Inc (ALDX) include a net sale of 2,074,234 shares made by Perceptive Life Sciences Master Fund Ltd , a net sale of 41,305 shares made by Stephen Machatha , and a net sale of 26,402 shares made by Bruce Greenberg .

In summary, during the past 3 months, insiders sold 250,945 shares of Aldeyra Therapeutics Inc (ALDX) in total and bought 682,265 shares, with a net purchase of 431,320 shares. During the past 18 months, 3,007,444 shares of Aldeyra Therapeutics Inc (ALDX) were sold and 682,265 shares were bought by its insiders, resulting in a net sale of 2,325,179 shares.

Aldeyra Therapeutics Inc (ALDX)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Aldeyra Therapeutics Inc Insider Transactions

No Available Data

Joshua Reed Mailing Address

Above is the net worth, insider trading, and ownership report for Joshua Reed. You might contact Joshua Reed via mailing address: C/o Aldeyra Therapeutics, Inc., 131 Hartwell Avenue, Suite 320, Lexington Ma 02421.

Discussions on Joshua Reed

No discussions yet.